Amrut Ambardekar
Concepts (422)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart-Assist Devices | 37 | 2024 | 537 | 8.400 |
Why?
| Heart Failure | 51 | 2024 | 2158 | 6.310 |
Why?
| Heart Transplantation | 24 | 2024 | 710 | 4.970 |
Why?
| Amyloidosis | 4 | 2023 | 39 | 1.840 |
Why?
| Cardiomyopathies | 9 | 2025 | 337 | 1.760 |
Why?
| Heart Ventricles | 9 | 2020 | 768 | 1.620 |
Why?
| Cardiomyopathy, Dilated | 9 | 2020 | 377 | 1.120 |
Why?
| Ventricular Dysfunction, Left | 8 | 2023 | 386 | 1.070 |
Why?
| Cardiomyopathy, Hypertrophic | 2 | 2024 | 131 | 0.990 |
Why?
| Myocardium | 10 | 2023 | 973 | 0.950 |
Why?
| Arrhythmias, Cardiac | 6 | 2022 | 317 | 0.870 |
Why?
| Ventricular Dysfunction, Right | 3 | 2020 | 228 | 0.850 |
Why?
| Myocytes, Cardiac | 11 | 2023 | 495 | 0.850 |
Why?
| Humans | 101 | 2025 | 129126 | 0.840 |
Why?
| Defibrillators, Implantable | 4 | 2020 | 295 | 0.830 |
Why?
| Rejuvenation | 1 | 2022 | 18 | 0.790 |
Why?
| Assisted Circulation | 2 | 2021 | 25 | 0.780 |
Why?
| Transplant Recipients | 4 | 2021 | 151 | 0.770 |
Why?
| Aortic Valve Insufficiency | 1 | 2022 | 47 | 0.770 |
Why?
| Echocardiography | 7 | 2017 | 627 | 0.750 |
Why?
| Fibrosis | 5 | 2022 | 522 | 0.750 |
Why?
| Hemodynamics | 7 | 2023 | 1084 | 0.730 |
Why?
| Stroke Volume | 9 | 2024 | 590 | 0.730 |
Why?
| Immunosuppressive Agents | 5 | 2021 | 690 | 0.710 |
Why?
| Calcineurin Inhibitors | 1 | 2021 | 59 | 0.710 |
Why?
| Vascular Stiffness | 2 | 2017 | 476 | 0.710 |
Why?
| Giant Cells | 1 | 2020 | 22 | 0.710 |
Why?
| Arteries | 1 | 2022 | 267 | 0.690 |
Why?
| Aortic Diseases | 1 | 2021 | 114 | 0.680 |
Why?
| Heart Neoplasms | 1 | 2020 | 49 | 0.680 |
Why?
| Ventricular Function, Left | 7 | 2023 | 528 | 0.670 |
Why?
| Sarcoma, Kaposi | 1 | 2020 | 76 | 0.670 |
Why?
| Coronary Vessels | 2 | 2018 | 236 | 0.650 |
Why?
| Myocarditis | 1 | 2020 | 98 | 0.640 |
Why?
| Ventricular Function, Right | 4 | 2020 | 276 | 0.630 |
Why?
| Middle Aged | 36 | 2025 | 31079 | 0.620 |
Why?
| Brugada Syndrome | 2 | 2009 | 9 | 0.610 |
Why?
| Graft Rejection | 3 | 2021 | 558 | 0.610 |
Why?
| Myocardial Contraction | 4 | 2020 | 331 | 0.600 |
Why?
| Heart | 6 | 2023 | 639 | 0.580 |
Why?
| Bariatric Surgery | 1 | 2021 | 192 | 0.570 |
Why?
| Extracellular Matrix | 1 | 2021 | 498 | 0.560 |
Why?
| Male | 48 | 2025 | 63201 | 0.560 |
Why?
| Myocardial Ischemia | 4 | 2019 | 249 | 0.540 |
Why?
| Ventricular Remodeling | 3 | 2021 | 258 | 0.540 |
Why?
| Female | 48 | 2025 | 68517 | 0.510 |
Why?
| Cryosurgery | 1 | 2016 | 54 | 0.490 |
Why?
| Thrombosis | 2 | 2016 | 323 | 0.490 |
Why?
| Heart Rate | 2 | 2021 | 808 | 0.480 |
Why?
| Amyloid Neuropathies, Familial | 2 | 2025 | 14 | 0.480 |
Why?
| Surgical Procedures, Operative | 1 | 2017 | 246 | 0.460 |
Why?
| Aged | 22 | 2025 | 22089 | 0.450 |
Why?
| Tachycardia, Ventricular | 1 | 2016 | 169 | 0.450 |
Why?
| Blood Pressure | 5 | 2022 | 1735 | 0.430 |
Why?
| Electrocardiography | 4 | 2020 | 607 | 0.430 |
Why?
| Marijuana Abuse | 1 | 2016 | 229 | 0.420 |
Why?
| Treatment Outcome | 13 | 2024 | 10226 | 0.410 |
Why?
| Aorta, Thoracic | 1 | 2015 | 261 | 0.410 |
Why?
| Physician-Patient Relations | 1 | 2017 | 531 | 0.400 |
Why?
| Myofibrils | 3 | 2022 | 50 | 0.400 |
Why?
| Patient-Centered Care | 2 | 2021 | 493 | 0.390 |
Why?
| Guideline Adherence | 3 | 2011 | 525 | 0.370 |
Why?
| Adult | 21 | 2023 | 35512 | 0.360 |
Why?
| Patient Compliance | 2 | 2017 | 562 | 0.350 |
Why?
| Cardiology | 2 | 2023 | 267 | 0.350 |
Why?
| Prealbumin | 3 | 2025 | 28 | 0.340 |
Why?
| Recovery of Function | 2 | 2011 | 648 | 0.340 |
Why?
| Cardiac Tamponade | 1 | 2010 | 14 | 0.340 |
Why?
| Risk Assessment | 6 | 2021 | 3260 | 0.330 |
Why?
| Hospitals, Rural | 1 | 2009 | 35 | 0.330 |
Why?
| Calcium | 4 | 2023 | 1180 | 0.330 |
Why?
| RNA, Long Noncoding | 2 | 2022 | 178 | 0.330 |
Why?
| Electric Stimulation Therapy | 1 | 2010 | 60 | 0.330 |
Why?
| Sarcomeres | 3 | 2022 | 92 | 0.320 |
Why?
| Baroreflex | 2 | 2021 | 60 | 0.320 |
Why?
| Cannabis | 1 | 2016 | 436 | 0.320 |
Why?
| Cardiac Output | 3 | 2023 | 155 | 0.320 |
Why?
| Safety | 1 | 2011 | 329 | 0.320 |
Why?
| Automobile Driving | 1 | 2011 | 141 | 0.320 |
Why?
| Hospitals, Urban | 1 | 2009 | 134 | 0.320 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2437 | 0.310 |
Why?
| Cardiac Pacing, Artificial | 1 | 2009 | 84 | 0.310 |
Why?
| Registries | 6 | 2021 | 1884 | 0.310 |
Why?
| Pulsatile Flow | 2 | 2018 | 59 | 0.300 |
Why?
| Vascular Remodeling | 2 | 2021 | 181 | 0.290 |
Why?
| Mineralocorticoid Receptor Antagonists | 2 | 2023 | 45 | 0.290 |
Why?
| Mastitis | 1 | 2007 | 4 | 0.290 |
Why?
| Counseling | 1 | 2011 | 386 | 0.290 |
Why?
| Puerperal Disorders | 1 | 2007 | 30 | 0.280 |
Why?
| Diagnosis, Differential | 4 | 2019 | 1417 | 0.280 |
Why?
| Quality Assurance, Health Care | 1 | 2009 | 317 | 0.280 |
Why?
| Length of Stay | 2 | 2009 | 1123 | 0.280 |
Why?
| Coronary Disease | 1 | 2009 | 384 | 0.270 |
Why?
| Prospective Studies | 10 | 2021 | 7079 | 0.270 |
Why?
| Environment | 1 | 2009 | 347 | 0.270 |
Why?
| Retrospective Studies | 13 | 2023 | 14571 | 0.260 |
Why?
| Follow-Up Studies | 6 | 2021 | 4915 | 0.250 |
Why?
| Diastole | 2 | 2018 | 151 | 0.250 |
Why?
| HIV Infections | 1 | 2020 | 2715 | 0.250 |
Why?
| Inpatients | 1 | 2009 | 464 | 0.240 |
Why?
| Troponin I | 2 | 2019 | 75 | 0.240 |
Why?
| Heart Failure, Systolic | 2 | 2024 | 25 | 0.230 |
Why?
| Quality of Health Care | 1 | 2009 | 608 | 0.230 |
Why?
| Perioperative Care | 2 | 2017 | 149 | 0.220 |
Why?
| Quality of Life | 6 | 2024 | 2694 | 0.220 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 10 | 0.210 |
Why?
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 37 | 0.210 |
Why?
| Preoperative Care | 2 | 2017 | 342 | 0.210 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2021 | 2065 | 0.200 |
Why?
| Heart Injuries | 1 | 2023 | 36 | 0.200 |
Why?
| Patient Transfer | 2 | 2019 | 164 | 0.200 |
Why?
| MicroRNAs | 2 | 2022 | 677 | 0.200 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2022 | 42 | 0.200 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2023 | 90 | 0.200 |
Why?
| Metalloproteases | 1 | 2022 | 43 | 0.200 |
Why?
| Hospitalization | 4 | 2024 | 2077 | 0.200 |
Why?
| Sequence Analysis, RNA | 2 | 2021 | 428 | 0.200 |
Why?
| Cohort Studies | 6 | 2023 | 5407 | 0.200 |
Why?
| Cadherin Related Proteins | 1 | 2022 | 12 | 0.190 |
Why?
| Triage | 1 | 2024 | 213 | 0.190 |
Why?
| Matrix Metalloproteinases, Secreted | 1 | 2021 | 11 | 0.190 |
Why?
| Long Term Adverse Effects | 1 | 2021 | 11 | 0.190 |
Why?
| ADAMTS4 Protein | 1 | 2021 | 15 | 0.190 |
Why?
| Succinic Acid | 2 | 2019 | 38 | 0.190 |
Why?
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.190 |
Why?
| Leukopenia | 1 | 2021 | 28 | 0.190 |
Why?
| Cation Transport Proteins | 1 | 2022 | 129 | 0.190 |
Why?
| Cardiovascular System | 1 | 2023 | 139 | 0.180 |
Why?
| Calcium-Binding Proteins | 1 | 2022 | 211 | 0.180 |
Why?
| Prognosis | 5 | 2025 | 3788 | 0.180 |
Why?
| Pressoreceptors | 1 | 2021 | 21 | 0.180 |
Why?
| Carrier Proteins | 2 | 2022 | 732 | 0.180 |
Why?
| Mycophenolic Acid | 1 | 2021 | 92 | 0.180 |
Why?
| Case-Control Studies | 4 | 2022 | 3342 | 0.180 |
Why?
| Muscle Proteins | 1 | 2022 | 229 | 0.170 |
Why?
| Myocardial Infarction | 2 | 2023 | 1014 | 0.170 |
Why?
| Alternative Splicing | 1 | 2022 | 218 | 0.170 |
Why?
| Hypertension | 2 | 2020 | 1243 | 0.170 |
Why?
| Cell Adhesion | 2 | 2018 | 445 | 0.170 |
Why?
| Immunohistochemistry | 2 | 2021 | 1671 | 0.170 |
Why?
| Disease Progression | 2 | 2018 | 2613 | 0.160 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 257 | 0.160 |
Why?
| Myocardial Reperfusion Injury | 1 | 2020 | 121 | 0.160 |
Why?
| HIV | 1 | 2020 | 226 | 0.160 |
Why?
| Terminology as Topic | 1 | 2020 | 200 | 0.160 |
Why?
| Severity of Illness Index | 5 | 2021 | 2739 | 0.160 |
Why?
| Consensus | 4 | 2023 | 638 | 0.150 |
Why?
| Aortic Valve | 1 | 2022 | 350 | 0.150 |
Why?
| United States | 9 | 2023 | 13939 | 0.150 |
Why?
| Cell Culture Techniques | 1 | 2021 | 346 | 0.150 |
Why?
| Exercise Test | 4 | 2023 | 615 | 0.150 |
Why?
| Clinical Decision-Making | 2 | 2020 | 305 | 0.150 |
Why?
| Longitudinal Studies | 3 | 2016 | 2716 | 0.150 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2020 | 173 | 0.150 |
Why?
| Mice | 11 | 2023 | 16644 | 0.150 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 231 | 0.150 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2021 | 224 | 0.150 |
Why?
| Filamins | 1 | 2018 | 28 | 0.140 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2018 | 182 | 0.140 |
Why?
| Mitochondrial Proteins | 1 | 2019 | 245 | 0.140 |
Why?
| Recurrence | 1 | 2020 | 1003 | 0.140 |
Why?
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 12 | 0.140 |
Why?
| Pilot Projects | 3 | 2019 | 1567 | 0.140 |
Why?
| Mutation | 2 | 2018 | 3700 | 0.140 |
Why?
| Anesthetics | 1 | 2017 | 53 | 0.140 |
Why?
| Cerebrovascular Circulation | 1 | 2018 | 221 | 0.140 |
Why?
| Caliciviridae Infections | 1 | 2016 | 17 | 0.130 |
Why?
| Immunity, Cellular | 1 | 2018 | 267 | 0.130 |
Why?
| PTEN Phosphohydrolase | 1 | 2018 | 157 | 0.130 |
Why?
| Transcriptome | 2 | 2020 | 883 | 0.130 |
Why?
| ErbB Receptors | 1 | 2020 | 603 | 0.130 |
Why?
| Brain | 2 | 2018 | 2628 | 0.130 |
Why?
| Time Factors | 5 | 2024 | 6518 | 0.130 |
Why?
| Down-Regulation | 2 | 2016 | 634 | 0.130 |
Why?
| Self Care | 1 | 2019 | 368 | 0.130 |
Why?
| Animals | 14 | 2023 | 34600 | 0.130 |
Why?
| Transition to Adult Care | 1 | 2017 | 76 | 0.130 |
Why?
| Polypharmacy | 1 | 2017 | 84 | 0.130 |
Why?
| Histone Deacetylases | 1 | 2018 | 209 | 0.130 |
Why?
| Myocytes, Smooth Muscle | 1 | 2018 | 245 | 0.130 |
Why?
| Prosthesis Design | 3 | 2014 | 308 | 0.130 |
Why?
| Eligibility Determination | 1 | 2016 | 63 | 0.130 |
Why?
| Cell Differentiation | 2 | 2021 | 1901 | 0.130 |
Why?
| Clinical Trials as Topic | 1 | 2020 | 1000 | 0.130 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2016 | 66 | 0.130 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2020 | 508 | 0.130 |
Why?
| Drug Interactions | 1 | 2017 | 360 | 0.120 |
Why?
| Nonprescription Drugs | 1 | 2016 | 69 | 0.120 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 391 | 0.120 |
Why?
| Receptors, Adrenergic, beta-1 | 1 | 2015 | 46 | 0.120 |
Why?
| Positron-Emission Tomography | 1 | 2017 | 283 | 0.120 |
Why?
| Tacrolimus | 1 | 2016 | 140 | 0.120 |
Why?
| Gene Expression Profiling | 2 | 2021 | 1689 | 0.120 |
Why?
| Antiviral Agents | 1 | 2021 | 706 | 0.120 |
Why?
| Postoperative Care | 1 | 2017 | 243 | 0.120 |
Why?
| Phosphorylation | 3 | 2019 | 1687 | 0.120 |
Why?
| Hospital Mortality | 2 | 2009 | 844 | 0.120 |
Why?
| Proportional Hazards Models | 3 | 2020 | 1210 | 0.120 |
Why?
| Viscosity | 1 | 2015 | 89 | 0.120 |
Why?
| Prescription Drugs | 1 | 2016 | 116 | 0.120 |
Why?
| Partial Thromboplastin Time | 1 | 2014 | 49 | 0.120 |
Why?
| Hypoglycemic Agents | 1 | 2023 | 1217 | 0.120 |
Why?
| Health Status | 1 | 2019 | 751 | 0.110 |
Why?
| Elastic Modulus | 1 | 2015 | 123 | 0.110 |
Why?
| Biomarkers | 3 | 2023 | 3896 | 0.110 |
Why?
| Cardiovascular Agents | 2 | 2020 | 152 | 0.110 |
Why?
| Rats | 5 | 2022 | 5173 | 0.110 |
Why?
| Coronary Artery Disease | 1 | 2020 | 678 | 0.110 |
Why?
| Attitude to Health | 1 | 2017 | 431 | 0.110 |
Why?
| Hip Prosthesis | 1 | 2014 | 35 | 0.110 |
Why?
| Systole | 1 | 2014 | 191 | 0.110 |
Why?
| Ambulatory Care | 1 | 2017 | 506 | 0.110 |
Why?
| Vaccination | 1 | 2022 | 1349 | 0.110 |
Why?
| Transcription, Genetic | 1 | 2020 | 1403 | 0.110 |
Why?
| Patient Selection | 2 | 2017 | 665 | 0.110 |
Why?
| Shock, Cardiogenic | 1 | 2014 | 59 | 0.110 |
Why?
| Atherosclerosis | 1 | 2018 | 410 | 0.110 |
Why?
| Incidence | 3 | 2019 | 2635 | 0.110 |
Why?
| Prosthesis Failure | 1 | 2014 | 120 | 0.100 |
Why?
| Liver Transplantation | 1 | 2020 | 799 | 0.100 |
Why?
| Quality Improvement | 1 | 2021 | 1099 | 0.100 |
Why?
| Blood Coagulation | 1 | 2014 | 226 | 0.100 |
Why?
| Marijuana Smoking | 1 | 2016 | 239 | 0.100 |
Why?
| Patient Education as Topic | 1 | 2017 | 736 | 0.100 |
Why?
| Young Adult | 6 | 2019 | 12389 | 0.100 |
Why?
| Ventricular Premature Complexes | 1 | 2012 | 35 | 0.100 |
Why?
| Attitude of Health Personnel | 2 | 2017 | 1098 | 0.090 |
Why?
| Nuclear Proteins | 1 | 2016 | 660 | 0.090 |
Why?
| Reproducibility of Results | 2 | 2019 | 3033 | 0.090 |
Why?
| Natriuretic Peptides | 1 | 2011 | 9 | 0.090 |
Why?
| Biopsy | 1 | 2015 | 1086 | 0.090 |
Why?
| Risk Factors | 4 | 2020 | 9768 | 0.090 |
Why?
| Neurotransmitter Agents | 1 | 2011 | 80 | 0.090 |
Why?
| Kaplan-Meier Estimate | 2 | 2010 | 864 | 0.090 |
Why?
| Decision Making | 1 | 2017 | 851 | 0.090 |
Why?
| Transforming Growth Factor beta1 | 2 | 2022 | 155 | 0.090 |
Why?
| Connectin | 2 | 2022 | 32 | 0.090 |
Why?
| Gene Expression Regulation | 3 | 2020 | 2508 | 0.090 |
Why?
| Receptors, Adrenergic, beta | 1 | 2011 | 126 | 0.090 |
Why?
| Endpoint Determination | 2 | 2020 | 75 | 0.090 |
Why?
| Stroke | 1 | 2019 | 1067 | 0.090 |
Why?
| Task Performance and Analysis | 1 | 2011 | 173 | 0.090 |
Why?
| Sensitivity and Specificity | 1 | 2015 | 1825 | 0.080 |
Why?
| Anticoagulants | 1 | 2014 | 614 | 0.080 |
Why?
| Pericardial Effusion | 1 | 2010 | 20 | 0.080 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 201 | 0.080 |
Why?
| Extracellular Matrix Proteins | 1 | 2011 | 141 | 0.080 |
Why?
| Heart Septum | 1 | 2009 | 26 | 0.080 |
Why?
| Comorbidity | 2 | 2020 | 1547 | 0.080 |
Why?
| Myocardial Revascularization | 1 | 2009 | 69 | 0.080 |
Why?
| DNA | 1 | 2016 | 1392 | 0.080 |
Why?
| Cells, Cultured | 3 | 2022 | 4010 | 0.080 |
Why?
| Exercise | 1 | 2020 | 1950 | 0.080 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 1275 | 0.080 |
Why?
| Adrenergic beta-Antagonists | 1 | 2011 | 319 | 0.080 |
Why?
| Disease Models, Animal | 4 | 2022 | 3953 | 0.080 |
Why?
| Ultrasonography | 1 | 2012 | 724 | 0.080 |
Why?
| Europe | 2 | 2020 | 362 | 0.080 |
Why?
| Transcription Factors | 1 | 2016 | 1632 | 0.070 |
Why?
| Coronary Circulation | 1 | 2008 | 137 | 0.070 |
Why?
| Syndrome | 1 | 2008 | 337 | 0.070 |
Why?
| Cardiac Catheterization | 2 | 2020 | 515 | 0.070 |
Why?
| Body Temperature | 1 | 2007 | 216 | 0.070 |
Why?
| Evidence-Based Medicine | 1 | 2011 | 718 | 0.070 |
Why?
| Blood Flow Velocity | 1 | 2008 | 411 | 0.070 |
Why?
| Continuity of Patient Care | 1 | 2009 | 279 | 0.070 |
Why?
| Delivery of Health Care | 2 | 2023 | 894 | 0.060 |
Why?
| Genetic Predisposition to Disease | 3 | 2020 | 2267 | 0.060 |
Why?
| Survivors | 1 | 2009 | 463 | 0.060 |
Why?
| Kidney Diseases | 1 | 2009 | 368 | 0.060 |
Why?
| Mice, Knockout | 2 | 2022 | 2765 | 0.060 |
Why?
| Clinical Protocols | 2 | 2017 | 254 | 0.060 |
Why?
| Practice Guidelines as Topic | 2 | 2009 | 1493 | 0.060 |
Why?
| Benzoxazoles | 1 | 2024 | 19 | 0.060 |
Why?
| Education, Medical, Graduate | 1 | 2009 | 439 | 0.060 |
Why?
| Natriuretic Peptide, Brain | 1 | 2024 | 99 | 0.060 |
Why?
| Sarcoplasmic Reticulum | 1 | 2023 | 44 | 0.050 |
Why?
| Genotype | 2 | 2020 | 1832 | 0.050 |
Why?
| Troponin | 1 | 2023 | 50 | 0.050 |
Why?
| Cytokines | 1 | 2011 | 1987 | 0.050 |
Why?
| Travel | 1 | 2023 | 121 | 0.050 |
Why?
| Cross-Sectional Studies | 3 | 2020 | 5070 | 0.050 |
Why?
| Histone Deacetylase 6 | 1 | 2022 | 19 | 0.050 |
Why?
| Practice Patterns, Physicians' | 1 | 2011 | 1269 | 0.050 |
Why?
| Disulfides | 1 | 2022 | 96 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 148 | 0.050 |
Why?
| Catecholamines | 1 | 2022 | 97 | 0.050 |
Why?
| Echocardiography, Doppler, Color | 1 | 2002 | 37 | 0.050 |
Why?
| Rats, Sprague-Dawley | 2 | 2018 | 2245 | 0.050 |
Why?
| RNA Splicing Factors | 1 | 2022 | 51 | 0.050 |
Why?
| Death, Sudden, Cardiac | 1 | 2023 | 179 | 0.050 |
Why?
| Calcium Channels | 1 | 2022 | 152 | 0.050 |
Why?
| Signal Transduction | 3 | 2021 | 4838 | 0.050 |
Why?
| Adolescent | 4 | 2019 | 20301 | 0.050 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2022 | 313 | 0.050 |
Why?
| Valsalva Maneuver | 1 | 2021 | 9 | 0.050 |
Why?
| Signal Processing, Computer-Assisted | 1 | 2002 | 143 | 0.050 |
Why?
| Anaerobic Threshold | 1 | 2021 | 27 | 0.050 |
Why?
| Phenylephrine | 1 | 2021 | 72 | 0.050 |
Why?
| Prevalence | 2 | 2018 | 2564 | 0.040 |
Why?
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.040 |
Why?
| Graft Survival | 1 | 2023 | 505 | 0.040 |
Why?
| Pharmacogenomic Testing | 1 | 2021 | 60 | 0.040 |
Why?
| Chronic Disease | 2 | 2017 | 1707 | 0.040 |
Why?
| Cardiomegaly | 1 | 2022 | 170 | 0.040 |
Why?
| Antibiotics, Antineoplastic | 1 | 2021 | 120 | 0.040 |
Why?
| Protein Isoforms | 1 | 2022 | 379 | 0.040 |
Why?
| Survival Rate | 1 | 2025 | 1875 | 0.040 |
Why?
| Culture Media | 1 | 2021 | 167 | 0.040 |
Why?
| Mice, Inbred C57BL | 2 | 2022 | 5284 | 0.040 |
Why?
| HEK293 Cells | 1 | 2023 | 687 | 0.040 |
Why?
| Cytomegalovirus | 1 | 2021 | 153 | 0.040 |
Why?
| Heart Valve Diseases | 1 | 2002 | 151 | 0.040 |
Why?
| Seizures | 1 | 2023 | 399 | 0.040 |
Why?
| Heart Function Tests | 1 | 2020 | 60 | 0.040 |
Why?
| Fellowships and Scholarships | 1 | 2023 | 274 | 0.040 |
Why?
| Electric Countershock | 1 | 2020 | 106 | 0.040 |
Why?
| Cardiac Resynchronization Therapy | 1 | 2020 | 45 | 0.040 |
Why?
| Adenosine Triphosphate | 1 | 2022 | 471 | 0.040 |
Why?
| Acylation | 1 | 2019 | 28 | 0.040 |
Why?
| Norepinephrine | 1 | 2021 | 209 | 0.040 |
Why?
| Reactive Oxygen Species | 1 | 2022 | 579 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2024 | 7065 | 0.040 |
Why?
| Program Evaluation | 2 | 2017 | 876 | 0.040 |
Why?
| Gene Silencing | 1 | 2020 | 185 | 0.040 |
Why?
| Molecular Diagnostic Techniques | 1 | 2020 | 97 | 0.040 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 431 | 0.040 |
Why?
| Principal Component Analysis | 1 | 2020 | 184 | 0.040 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 83 | 0.040 |
Why?
| Methylation | 1 | 2019 | 227 | 0.040 |
Why?
| Internship and Residency | 1 | 2009 | 1061 | 0.040 |
Why?
| Coronary Angiography | 1 | 2020 | 306 | 0.040 |
Why?
| Cluster Analysis | 1 | 2020 | 478 | 0.040 |
Why?
| Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2020 | 335 | 0.040 |
Why?
| Fatty Acids | 1 | 2021 | 415 | 0.040 |
Why?
| Oxygen Consumption | 1 | 2021 | 675 | 0.040 |
Why?
| Hydroxamic Acids | 1 | 2018 | 88 | 0.040 |
Why?
| Fibroblasts | 1 | 2022 | 939 | 0.040 |
Why?
| Zebrafish | 1 | 2022 | 464 | 0.040 |
Why?
| Collagen | 1 | 2020 | 429 | 0.040 |
Why?
| Hyperplasia | 1 | 2018 | 170 | 0.040 |
Why?
| Lysine | 1 | 2019 | 278 | 0.040 |
Why?
| Myosins | 1 | 2018 | 133 | 0.030 |
Why?
| Fluorine Radioisotopes | 1 | 2017 | 11 | 0.030 |
Why?
| Alleles | 1 | 2020 | 845 | 0.030 |
Why?
| Autoradiography | 1 | 2017 | 74 | 0.030 |
Why?
| Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| Surveys and Questionnaires | 2 | 2021 | 5377 | 0.030 |
Why?
| Patient Reported Outcome Measures | 1 | 2020 | 369 | 0.030 |
Why?
| Atropine | 1 | 2016 | 24 | 0.030 |
Why?
| Loperamide | 1 | 2016 | 10 | 0.030 |
Why?
| Antidiarrheals | 1 | 2016 | 14 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2020 | 389 | 0.030 |
Why?
| Papio | 1 | 2017 | 91 | 0.030 |
Why?
| Tissue Donors | 1 | 2019 | 388 | 0.030 |
Why?
| Organ Culture Techniques | 1 | 2017 | 144 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2018 | 386 | 0.030 |
Why?
| Circadian Rhythm | 1 | 2020 | 409 | 0.030 |
Why?
| Transcription Elongation, Genetic | 1 | 2016 | 22 | 0.030 |
Why?
| Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| Gastrointestinal Agents | 1 | 2016 | 60 | 0.030 |
Why?
| Radiopharmaceuticals | 1 | 2017 | 166 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2018 | 206 | 0.030 |
Why?
| Disease Management | 1 | 2020 | 593 | 0.030 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2021 | 818 | 0.030 |
Why?
| Referral and Consultation | 1 | 2021 | 732 | 0.030 |
Why?
| 3' Untranslated Regions | 1 | 2016 | 140 | 0.030 |
Why?
| Actins | 1 | 2018 | 402 | 0.030 |
Why?
| Acetylation | 1 | 2016 | 237 | 0.030 |
Why?
| Drug Combinations | 1 | 2016 | 329 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2018 | 773 | 0.030 |
Why?
| Feasibility Studies | 1 | 2019 | 862 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2020 | 3383 | 0.030 |
Why?
| Survival Analysis | 1 | 2018 | 1265 | 0.030 |
Why?
| Self-Management | 1 | 2017 | 161 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 2018 | 417 | 0.030 |
Why?
| Cell Line | 1 | 2021 | 2737 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2020 | 1943 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 485 | 0.030 |
Why?
| Mental Health | 1 | 2021 | 684 | 0.030 |
Why?
| Factor X | 1 | 2014 | 25 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2020 | 2079 | 0.030 |
Why?
| Cobalt | 1 | 2014 | 51 | 0.030 |
Why?
| Reoperation | 1 | 2016 | 560 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2016 | 1021 | 0.030 |
Why?
| Action Potentials | 1 | 2017 | 471 | 0.030 |
Why?
| Models, Biological | 1 | 2021 | 1695 | 0.030 |
Why?
| Warfarin | 1 | 2014 | 147 | 0.030 |
Why?
| Mass Screening | 1 | 2021 | 1159 | 0.030 |
Why?
| Amino Acids, Aromatic | 1 | 2013 | 8 | 0.030 |
Why?
| Self Report | 1 | 2017 | 806 | 0.030 |
Why?
| Proteomics | 1 | 2019 | 1010 | 0.030 |
Why?
| Child, Preschool | 2 | 2019 | 10450 | 0.030 |
Why?
| RNA Polymerase II | 1 | 2016 | 317 | 0.030 |
Why?
| Creatine | 1 | 2013 | 55 | 0.030 |
Why?
| Heparin | 1 | 2014 | 240 | 0.030 |
Why?
| Glutamine | 1 | 2013 | 92 | 0.030 |
Why?
| Chromatin | 1 | 2016 | 478 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 1621 | 0.030 |
Why?
| Antibodies | 1 | 2014 | 391 | 0.020 |
Why?
| Cell Cycle Proteins | 1 | 2016 | 580 | 0.020 |
Why?
| Alanine | 1 | 2013 | 141 | 0.020 |
Why?
| Depression | 1 | 2021 | 1293 | 0.020 |
Why?
| RNA, Messenger | 1 | 2020 | 2676 | 0.020 |
Why?
| Medication Adherence | 1 | 2017 | 569 | 0.020 |
Why?
| Dyspnea | 1 | 2014 | 239 | 0.020 |
Why?
| Fatigue | 1 | 2014 | 320 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2018 | 872 | 0.020 |
Why?
| Lactic Acid | 1 | 2013 | 295 | 0.020 |
Why?
| Phenotype | 1 | 2020 | 3058 | 0.020 |
Why?
| Patient Discharge | 1 | 2016 | 857 | 0.020 |
Why?
| Sex Factors | 1 | 2015 | 1953 | 0.020 |
Why?
| Catheter Ablation | 1 | 2012 | 332 | 0.020 |
Why?
| Age Factors | 1 | 2015 | 3120 | 0.020 |
Why?
| Child | 2 | 2019 | 20805 | 0.020 |
Why?
| Glucose | 1 | 2013 | 983 | 0.020 |
Why?
| Focus Groups | 1 | 2009 | 455 | 0.020 |
Why?
| Glomerular Filtration Rate | 1 | 2009 | 682 | 0.020 |
Why?
| Infant | 1 | 2015 | 8992 | 0.010 |
Why?
| Clinical Competence | 1 | 2009 | 1021 | 0.010 |
Why?
| Observer Variation | 1 | 2002 | 315 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|